Temasek fund invests $800 mn in Alphabet subsidiary

Singapore-based sovereign fund Temasek will invest $800 million in Verily, the Alphabet subsidiary focused on healthcare announced on Thursday.

The infusion of cash, for which Temasek will get a , comes as Verily works to bring some of its creations to market.

The bulk of the money will be pumped into Verily in the coming days, and the rest in the second half of this year, according to Verily, formerly known as Google Life Sciences but rebranded after the became Alphabet in a corporate restructuring.

Verily is among Alphabet's "big bets" as the Silicon Valley giant stretches beyond its core and lucrative online search business for innovative new opportunities.

Verily specializes in applying technology to problems in health and biology, among ideas discussed has been building a sickness-sensing diagnostic device along the lines of the "tricorder" seen in "Star Trek" science fiction films and television shows.

Verily said in a release that it is creating tools and easy-to-use platforms to gather deep and broad sets of health information and organize them in ways that let actions be taken.

"With a substantial network and insights into the economies in Asia, Temasek will provide valuable guidance as we look to ex-US markets with our development partners," Verily chief executive Andrew Conrad said in a release.

To date, Verily is one of the few other bets at Alphabet that is making money.

Verily last year teamed with French pharmaceutical group Sanofi to "combine devices, software, medicine and professional care" to manage diabetes.

Verily also collaborates with Britain-based GlaxoSmithKline on "bioelectronic medicine," which it described as treating ailments by using miniature, implantable devices that can modify the body's electrical signals.

Explore further

Sanofi, Google launch diabetes joint venture

© 2017 AFP

Citation: Temasek fund invests $800 mn in Alphabet subsidiary (2017, January 26) retrieved 20 October 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors